Role of cannabinoids in the regulation of bone remodeling

Frontiers in Endocrinology

Volumn 3, Issue NOV, 2012, Pages

  Idris, Aymen I ^a   Ralston, Stuart H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Adipocytes; Bone; Cannabinoid; CB1,CB2; GPR55; Osteoblasts; Osteoclasts

Indexed keywords

EID: 84876329281     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00136     Document Type: Review

References (88)

1. Abed, E., Labelle, D., Martineau, C., Loghin, A., and Moreau, R. (2009). Expression of transient receptor potential (TRP) channels in human and murine osteoblast-like cells. Mol. Membr. Biol. 26, 146-158.
2. Bab, I., Ofek, O., Tam, J., Rehnelt, J., and Zimmer, A. (2008). Endo-cannabinoids and the regulation of bone metabolism. J. Neuroendocrinol. 20(Suppl. 1), 69-74.
3. Basavarajappa, B. S., (2007). Critical enzymes involved in endocannabinoid metabolism. Protein Pept.Lett. 14,237-246.
4. Begg, M., Pacher, P., Batkai, S., Osei-Hyiaman, D., Offertaler, L., Mo, F. M., et al. (2005). Evidence for novel cannabinoid receptors. Phar-macol.Ther. 106,133-145.
5. Bouaboula, M., Dussossoy, D., and Casellas, P. (1999). Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J.Biol.Chem. 274, 20397-20405.
6. Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., et al. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272, 22330-22339.
7. Bouaboula, M., Poinot-Chazel, C., Marchand, J., Canat, X., Bour-rie, B., Rinaldi-Carmona, M., et al. (1996). Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237, 704-711.
8. Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., et al. (1993). Cannabinoid-receptor expression in human leukocytes. Eur.J.Biochem. 214, 173-180.
9. Carayon, P., Marchand, J., Dussossoy, D., Derocq, J. M., Jbilo, O., Bord, A., et al. (1998). Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92,3605-3615.
10. Chicca, A., Marazzi, J., Nicolussi, S., and Gertsch, J. (2012). Evidence for bidirectional endocannabinoid transport across cell membranes. J.Biol.Chem. 287,34660-34682.
11. Daaka, Y., Zhu, W., Friedman, H., and Klein, T. W. (1997). Induction of interleukin-2 receptor alpha gene by delta9-tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1 cannabinoid receptor. DNA Cell Biol. 16,301-309.
12. Demuth, D. G., and Molleman, A. (2006). Cannabinoid signalling. Life Sci. 78, 549-563.
13. Derkinderen, P., Toutant, M., Bur-gaya, F., Le, B. M., Siciliano, J. C., De, F., et al. (1996). Regulation of a neuronal form of focal adhesion kinase by anandamide. Science 273, 1719-1722.
14. DiMarzo,V. (2008). Targeting the endo-cannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov. 7, 438-455.
15. Di Marzo, V., De Petrocellis, L., Fezza, F., Ligresti, A., and Bisogno, T. (2002). Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids 66,377-391.
16. Di Marzo, V., De Petrocellis, L., Sepe, N., and Buono, A. (1996). Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neu-roblastoma cells. Biochem. J. 316, 977-984.
17. Dinh, T. P., Freund, T. F., and Piomelli, D. (2002). A role for monoglyceride lipase in 2-arachidonoylglycerol inac-tivation. Chem. Phys. Lipids 121, 149-158.
18. Felder, C. C., Briley, E. M., Axelrod, J., Simpson, J. T., Mackie, K., and Devane, W. A. (1993). Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. U.S.A. 90, 7656-7660.
19. Felder, C. C., Nielsen, A., Briley, E. M., Palkovits, M., Priller, J., Axelrod, J., et al. (1996). Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393, 231-235.
20. Fowler, C. J. (2012). Anandamide uptake explained? Trends Pharma-col.Sci. 33, 181-185.
21. Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur.J.Biochem. 232,54-61.
22. Gatley, S. J., Gifford, A. N., Volkow, N. D., Lan, R., and Makriyannis, A. (1996). 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol. 307, 331-338.
23. Gatley, S. J., Lan, R., Pyatt, B., Gifford, A. N., Volkow, N. D., and Makriyannis, A. (1997). Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. 61,PL191-PL197.
24. Geng, D., Xu, Y., Yang, H., Wang, J., Zhu, X., Zhu, G., et al. (2010). Protection against titanium particle induced osteolysis by cannabinoid receptor 2 selective antagonist. Bio-materials 31,1996-2000.
25. George, K. L., Saltman, L. H., Stein, G. S., Lian, J. B., and Zurier, R. B. (2008). Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteo-clastogenesis in mononuclear precursor cells, and induces apoptosis in mature osteoclast-like cells. J. Cell Physiol. 214, 714-720.
26. Gimble, J. M., Zvonic, S., Floyd, Z. E., Kassem, M., and Nuttall, M. E. (2006). Playing with bone and fat. J.Cell. Biochem. 98, 251-266.
27. Grant, I., and Cahn, B. R. (2005). Cannabis and endocannabinoid modulators: therapeutic promises and challenges. Clin. Neurosci. Res. 5, 185-199.
28. Guzman, M., Galve-Roperh, I., and Sanchez, C. (2001a). Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol. Sci. 22, 19-22
29. Guzman, M., Sanchez, C., and Galve-Roperh, I. (200 1b).Control of the cell survival/death decision by cannabinoids. J. Mol. Med. 78, 613-625
30. Hermann, A., Kaczocha, M., and Deutsch, D. G. (2006). 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook. AAPSJ. 8,E409-E412.
31. Ho, B. Y., Current, L., and Drewett, J. G. (2002). Role of intracellular loops of cannabinoid CB(1) receptor in functional interaction with G(alpha16). FEBS Lett. 522, 130-134.
32. Hosohata, K., Quock, R. M., Hosohata, Y., Burkey, T. H., Makriyannis, A., Consroe, P., et al. (1997a). AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci. 61, L1 15-L118.
33. Hosohata, Y., Quock, R. M., Hosohata, K., Makriyannis, A., Consroe, P., Roeske, W. R., et al. (1997b). AM630 antagonism of cannabinoid-stimulated [35S]GTP gammaS binding in the mouse brain. Eur. J. Pharmacol. 321,R1-R3.
34. Idris, A. I., Sophocleous, A., Landao-Bassonga, E., Canals, M., Milligan, G., Baker, D., et al. (2009). Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab. 10, 139-147.
35. Idris, A. I., Sophocleous, A., Landao-Bassonga, E., Vant Hof, R. J., and Ralston, S. H. (2008). Regulation of bone mass, osteoclast function and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 149, 5619-5626.
36. Idris, A. I., Van t Hof, R. J., Greig, I. R., Ridge, S. A., Baker, D., Ross, R. A., et al. (2005). Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med. 11,774-779.
37. Kapur, A., Zhao, P., Sharir, H., Bai, Y., Caron, M. G., Barak, L. S., et al. (2009). Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem. 284,29817-29827.
38. Karanian, D. A., Brown, Q. B., Makriyannis, A., and Bahr, B. A. (2005). Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus. Eur. J. Pharmacol. 508, 47-56.
39. Klein, T. W., Lane, B., Newton, C. A., and Friedman, H. (2000). The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. 225,1-8.
40. Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., et al. (2003). The cannabinoid system and immune modulation. J. Leukoc. Biol. 74,486-496.
41. Ko, J. Y., Wu, R. W., Kuo, S. J., Chen, M. W., Yeh, D. W., Ke, H. C., et al. (2012). Cannabinoid receptor 1 mediates glucocorticoid-induced bone loss in rats by perturbing bone mineral acquisition and marrow adi-pogenesis. Arthritis Rheum. 64,1204-1214.
42. Kondo, S., Kondo, H., Nakane, S., Kodaka, T., Tokumura, A., Waku, K., et al. (1998). 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacyl-glycerols in various rat tissues, and evidence for its generation through CA2+-dependent and -independent mechanisms. FEBS Lett. 429, 152-156.
43. Lan, R., Liu, Q., Fan, P., Lin, S., Fernando, S. R., McCallion, D., et al. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 42, 769-776.
44. Landsman, R. S., Makriyannis, A., Deng, H., Consroe, P., Roeske, W. R., and Yamamura, H. I. (1998). AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sci. 62,L109-L113.
45. Lauckner, J. E., Jensen, J. B., Chen, H. Y., Lu, H. C., Hille, B., and Mackie, K. (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U.S.A. 105, 2699-2704.
46. Lunn, C. A., Fine, J., Rojas-Triana, A., Jackson, J. V., Lavey, B., Kozlowski, J. A., et al. (2007). Cannabinoid CB(2)-selective inverse agonist protects against antigen-induced bone loss. Immunopharmacol. Immunotox-icol. 29, 387-401.
47. Maccarrone, M., and Finazzi-Agro, A. (2002). Endocannabinoids and their actions. Vitam. Horm. 65, 225-255.
48. Maejima, T., Hashimoto, K., Yoshida, T., Aiba, A., and Kano, M. (2001a). Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31, 463-475.
49. Maejima, T., Ohno-Shosaku, T., and Kano, M. (2001b). Endogenous cannabinoid as a retrograde messenger from depolarized postsynap-tic neurons to presynaptic terminals. Neurosci.Res. 40, 205-210.
50. Marazzi, J., Kleyer, J., Paredes, J. M., and Gertsch, J. (2011). Endocannabinoid content in fetal bovine sera - unexpected effects on mononuclear cells and osteoclastogenesis. J. Immunol. Methods 373,219-228.
51. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
52. Mechoulam, R. (2005). Plant cannabinoids: a neglected pharmacological treasure trove. Br. J. Pharmacol. 146, 913-915.
53. Meschler, J. P., Kraichely, D. M., Wilken, G. H., and Howlett, A. C. (2000). Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophen-yl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem. Pharmacol. 60, 1315-1323.
54. Molina-Holgado, E., Vela, J.x M., revalo-Martin, A., Almazan, G., Molina-Holgado, F., Borrell, J., et al. (2002). Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci. 22, 9742-9753.
55. Munro, S., Thomas, K. L., and bu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
56. Nong, L., Newton, C., Friedman, H., and Klein, T. W. (2001). CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types. Adv. Exp. Med. Biol. 206, 229-233.
57. Ofek, O., Attar-Namdar, M., Kram, V., Dvir-Ginzberg, M., Mechoulam, R., Zimmer, A., et al. (2011). CB2 cannabinoid receptor targets mito-genic Gi protein-cyclin D1 axis in osteoblasts. J. Bone Miner. Res. 26, 308-316.
58. Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., et al. (2006). Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. U.S.A. 103, 696-701.
59. Palazuelos, J., Davoust, N., Julien, B., Hatterer, E., Aguado,T. Mechoulam, R., et al. (2008). The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal mo del of multiple sclerosis. J. Biol. Chem. 283,13320-13329
60. Pertwee, R. G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74,129-180
61. Pertwee, R. G. (2005). Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol. 1-51
62. Pertwee, R. G. (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156,397-411
63. Pertwee, R. G. (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17, 1360-1381
64. Pertwee, R. G., and Ross, R. A. (2002). Cannabinoid receptors and their lig-ands. Prostaglandins Leukot. Essent. Fatty Acids 66,101-121
65. Richardson, D., Pearson, R. G., Kurian, N., Latif, M. L., Garle, M. J., Barrett, D. A., et al. (2008). Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther. 10, R43.
66. Ridge, S. A., Ford, L., Cameron, G. A., Ross, R. A., and Rogers, M. J. (2007). Endocannabinoids are produced by bone cells and stimulate bone resorp-tion in vitro. Bone 40(Suppl. 1), S120.
67. Ross, R. A. (2003). Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 140,790-801.
68. Ross, R. A. (2009). The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 30, 156-163.
69. Ross, R. A., Brockie, H. C., Stevenson, L. A., Murphy, V. L., Templeton, E, Makriyannis, A., et al. (1999). Agonist-inverse agonist characteriza tion at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 126, 665- 672.
70. Rossi, F., Siniscalco, D., Luongo, L., De Petrocellis, L., Bellini, G., Petrosino, S., et al. (2009). The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone 44, 476-484.
71. Ryberg, E., Larsson, N., Sjogren, S., Hjorth, S., Hermansson, N. O., Leonova, J., et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092-1101.
72. Sanchez, M. G., Ruiz-Llorente, L., Sanchez, A. M., and Diaz-Laviada, I. (2003). Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal. 15,851-859.
73. Saunders, C. I., Kunde, D. A., Crawford, A., and Geraghty, D. P. (2007). Expression of transient receptor potential vanilloid 1 (TRPV1) and 2 (TRPV2) in human peripheral blood. Mol.Immunol. 44,1429-1435.
74. Schuehly, W., Paredes, J. M., Kleyer, J., Huefner, A., Anavi-Goffer, S., Raduner, S., et al. (2011). Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem. Biol. 18,1053-1064.
75. Scutt, A., and Williamson, E. M. (2007). Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif. Tissue Int. 80, 50-59.
76. Simon, G. M., and Cravatt, B. F. (2006). Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway.J. Biol. Chem. 281,26465-26472.
77. Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., et al. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129, 227-230.
78. Sophocleous, A., Landao-Bassonga, E., vant Hof, R. J., Idris, A. I., and Ralston, S. H. (2011). The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation. Endocrinology 152, 2141-2149.
79. Sophocleous, A., Ralston, S. H., and Idris, A. I. (2012). Combined deficiency of the CB1 and CB2 receptors enhances peak bone mass by inhibiting osteoclast differentiation but increases age-related bone loss by promoting adipocyte differentiation and reducing osteoblast differentiation. Bone 50,S32.
80. Stella, N., Schweitzer, P., and Piomelli, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.
81. Tam, J., Ofek, O., Fride, E., Ledent, C., Gabet, Y., Muller, R., et al. (2006). Involvement of neuronal cannabinoid receptor, CB1, in regulation of bone mass and bone remodeling. Mol. Pharmacol. 70, 786-792.
82. Tam, J., Trembovler, V., Di, M., Petrosino, V. S., Leo, G., Alexandrovich, A., et al. (2008). The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J. 22, 285-294.
83. Van Der Stelt, M., and Di Marzo, V. (2005). Anandamide as an intracellu-lar messenger regulating ion channel activity. Prostaglandins Other Lipid Mediat. 77, 111-122.
84. Van Der, S. M., Trevisani, M., Vel-lani, V., De, P. L., Schiano, M. A., Campi, B., et al. (2005). Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J. 24, 3026-3037.
85. Wan, Y., Chong, L.W., and Evans, R. M. (2007). PPAR-gamma regulates osteoclastogenesis in mice. Nat.Med. 13,1496-1503.
86. Whyte, L. S., Ford, L., Ridge, S. A., Cameron, G. A., Rogers, M. J., and Ross, R. A. (2012). Cannabinoids, and bone: endocannabinoids modulate human osteoclast function in vitro. Br. J. Pharmacol. 165, 2584-2597..
87. Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., et al. (2009). The putative cannabi-noid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. U.S.A. 106,16511-16516.
88. Wu, R. W., Lin, T. P., Ko, J. Y., Yeh, D. W., Chen, M. W., Ke, H. C., et al. (2011). Cannabinoid receptor 1 regulates ERK and GSK-3beta-dependent glu-cocorticoid inhibition of osteoblast differentiation in murine MC3T3-E1 cells. Bone 49, 1255-1263.